Lantern Pharma, Inc.

72 articles with Lantern Pharma, Inc.

• Lantern Pharma Reports Second Quarter 2022 Financial Results and Operational Highlights

  8/8/2022

  Lantern Pharma Inc. (NASDAQ: LTRN), a clinical stage biopharmaceutical company using its proprietary RADR® artificial intelligence ("A.I.") and machine learning (“M.L.”) platform to transform the cost, pace, and timeline of oncology drug discovery and development, today announced operational highlights and financial results for the second quarter ended June 30, 2022.

• Lantern Pharma to Report Second Quarter 2022 Operating & Financial Results on August 8th, 2022 at 4:30 p.m. ET

  8/1/2022

  Lantern Pharma Inc. (NASDAQ: LTRN), a clinical stage biopharmaceutical company using its proprietary RADR® artificial intelligence (A.I.) and machine learning (ML) platform to transform the cost, pace, and timeline of oncology drug discovery and development, today announced that it will host its second quarter 2022 financial results webcast on Monday, August 8th, 2022 at 4:30 p.m. Eastern Time / 1:30 p.m. Pacific Time.

• Lantern Pharma Receives FDA Authorization to Initiate its Phase 2 Clinical Trial, Harmonic™, for LP-300 in Never Smokers with Non-Small Cell Lung Cancer

  7/14/2022

  Lantern Pharma Inc. (NASDAQ: LTRN), a clinical stage biopharmaceutical company using its proprietary RADR® artificial intelligence ("A.I.") and machine learning (“ML”) platform to transform the cost, pace, and timeline of oncology drug discovery and development, today announced that the Food and Drug Administration (FDA) has cleared the Company to proceed with its Phase 2 clinical trial, Harmonic™, for its investigational new drug LP-300.

• Lantern Pharma to Host Virtual KOL Event on Glioblastoma Multiforme (GBM) with Collaborators from Johns Hopkins during Brain Tumor Awareness Month

  5/12/2022

  Lantern Pharma Inc. (NASDAQ: LTRN ),  a clinical stage biopharmaceutical company using its proprietary RADR ®  artificial intelligence ("A.I.") and machine learning (ML) platform to transform the cost, pace, and timeline of oncology drug discovery and development, today announced that it will host a virtual key opinion leader (KOL) webinar on May 26th, 2022 at 12:00 p.m. ET.

• Lantern Pharma Management to Speak at Multiple Investor and Scientific Conferences in May 2022

  5/5/2022

  Lantern Pharma Inc. today announced that the Company’s management will be speaking at five investor and scientific conferences in May 2022.

• Lantern Pharma Reports First Quarter 2022 Financial Results and Operational Highlights

  5/3/2022

  Lantern Pharma Inc., a clinical stage biopharmaceutical company using its proprietary RADR® artificial intelligence and machine learning platform to transform the cost, pace, and timeline of oncology drug discovery and development, announced financial results and operational highlights for the first quarter ended March 31, 2022.

• Lantern Pharma's Board of Directors Names Maria Maccecchini, Ph.D. as a Director Nominee to Lantern's Board of Directors

  4/26/2022

  Lantern Pharma Inc. today announced that Maria L. Maccecchini, Ph.D. has been named as a nominee for election to Lantern's Board of Directors.

• Lantern Pharma to Report First Quarter 2022 Operating & Financial Results on May 3rd, 2022 at 4:30 p.m. ET

  4/22/2022

  Lantern Pharma Inc. today announced that it will report its first quarter 2022 financial results on Tuesday, May 3, 2022, after the financial markets close.

• Lantern Pharma Announces Extension of Existing Share Repurchase Program

  3/22/2022

  Lantern Pharma Inc. announced that its Board of Directors has authorized an extension through July 31, 2022 of Lantern's existing share repurchase program to acquire up to $7 million of the Company's common stock.

• Lantern Pharma to Present Positive Preclinical Data on the Effectiveness of LP-184 in Brain Metastases at the American Association of Cancer Research (AACR) Annual Meeting

  3/14/2022

  Lantern Pharma Inc. (NASDAQ: LTRN), today announced that it will present positive preclinical data on the in vitro efficacy of its drug candidate LP-184 in brain metastases (mets) at the American Association of Cancer Research (AACR) annual meeting.

• Lantern Pharma Reports Fourth Quarter and Fiscal Year 2021 Financial Results and Operational Highlights

  3/10/2022

  Lantern Pharma Inc. announced financial results and operational highlights for the fourth quarter and fiscal year ended December 31, 2021.

• Lantern Pharma Inc. to Report Fourth Quarter and Full Year 2021 Financial Results on March 10, 2022

  3/3/2022

  Lantern Pharma announced today that it will host a conference call on Thursday, March 10th, 2022 at 4:30 p.m. Eastern Time / 1:30 p.m. Pacific Time.

• Lantern Pharma Expands into Additional Pediatric Cancers Through a Collaboration with The Greehey Children's Cancer Research Institute (GCCRI) at University of Texas Health Science Center-San Antonio

  2/15/2022

  Lantern Pharma today announced that it is expanding opportunities for its portfolio of drug candidates and A.I. drug discovery platform into additional rare pediatric cancers through a collaboration with The Greehey Children's Cancer Research Institute (GCCRI) at the University of Texas Health Science Center at San Antonio (UTHSCSA).

• Lantern Pharma Receives Rare Pediatric Disease and Orpan Drug Designations for LP-184 for the Treatment of Atypical Teratoid Rhabdoid Tumor (ATRT)

  1/24/2022

  Lantern Pharma today announced that the U.S. Food and Drug Administration (FDA) has granted both Rare Pediatric Disease Designation and Orphan Drug Designation for the company's drug candidate LP-184 for the treatment of pediatric patients with ATRT.

• Lantern Pharma Announces Collaboration & Research Agreement with The Danish Cancer Society Research Center to Support Clinical Development of Drug Candidates, LP-100 and LP-184, in Solid Tumors

  1/18/2022

  Lantern Pharma (NASDAQ: LTRN), a clinical stage biopharmaceutical company using its proprietary RADR® artificial intelligence ("A.I.") platform to transform the cost, pace, and timeline of oncology drug discovery and development, today announced a collaboration and research agreement with The Danish Cancer Society Research Center (DCRC) to support clinical development of Lantern's acylfulvene class drug candidates, LP-100 and LP-184.

• Lantern Pharma Expands Precision Oncology Collaboration with the National Cancer Institute - Accelerating Path to First in Human Clinical Trials for Drug Candidates LP-184 & LP-284

  1/12/2022

  Lantern Pharma announced it has expanded its collaboration agreement with the Developmental Therapeutics Branch of the National Cancer Institute of the National Institutes of Health.

• Lantern Pharma to Present at the H.C. Wainwright BioConnect 2022 Conference

  1/4/2022

  Lantern Pharma (NASDAQ: LTRN), today announced that Panna Sharma, Chief Executive Officer and President of Lantern Pharma, will be presenting at the H.C. Wainwright BioConnect 2022 Conference being held virtually January 10-13, 2022.

• Lantern Pharma Presents Positive Data on the Effectiveness of LP-284 in Hematologic Cancers at the 63rd American Society of Hematology (ASH) Annual Meeting

  12/14/2021

  Lantern Pharma (NASDAQ: LTRN), a clinical stage biopharmaceutical company using its proprietary RADR® artificial intelligence ("A.I.") platform to transform the cost, pace, and timeline of oncology drug discovery and development, today announced that Lantern Pharma presented positive data on the effectiveness of LP-284 in hematologic cancers at the 63rd American Society of Hematology (ASH) Annual Meeting,

• Lantern Pharma Announces Share Repurchase Program - Nov 22, 2021

  11/22/2021

  Lantern Pharma Inc., a clinical stage biopharmaceutical company using its proprietary RADR® artificial intelligence platform to transform the cost, pace, and timeline of oncology drug discovery and development, announced that its board of directors has authorized a share repurchase program to acquire up to $7 million of the Company's common stock.

• Lantern Pharma to Host Virtual KOL Event on the Potential Treatment of Pancreatic Cancer with Drug Candidate LP-184 on November 18th, World Pancreatic Cancer Day

  11/12/2021

  Lantern Pharma (NASDAQ: LTRN), today announced it will host a virtual Key Opinion Leader (KOL) event regarding the potential treatment of pancreatic cancer utilizing Lantern Pharma's drug candidate LP-184, on World Pancreatic Cancer Day.